Screener
Viking Therapeutics VKTX Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Revenues | Three Months Ended March 31, 2026 / — | Three Months Ended March 31, 2025 / — |
|---|---|---|
| Operating expenses: | ||
| Research and development | 150,150 | 41,391 |
| General and administrative | 13,975 | 14,078 |
| Total operating expenses | 164,125 | 55,469 |
| Loss from operations | (164,125) | (55,469) |
| Other income (expense): | ||
| Amortization of financing costs | — | (24) |
| Interest income, net | 5,800 | 9,864 |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's other operating expenses?
- Viking Therapeutics (VKTX) reported other operating expenses of $164.13M in Q1 2026.
- How has Viking Therapeutics's other operating expenses changed year-over-year?
- Viking Therapeutics's other operating expenses increased by 195.9% year-over-year, from $55.47M to $164.13M.
- What is the long-term trend for Viking Therapeutics's other operating expenses?
- Over 4 years (2021 to 2025), Viking Therapeutics's other operating expenses has grown at a 63.0% compound annual growth rate (CAGR), from $55.68M to $393.34M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Viking Therapeutics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude